Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 8/20 | 0.78 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.64 |
| ▸ | APP | P05067 | 1/20 | 0.64 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.59 |
| ▸ | NQO2 | P16083 | 1/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
| ▸ | FBP1 | P09467 | 1/20 | 0.54 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22468800 | 1.00 | NFE2L2 (0.78) | NFE2L2PTGS1APPHSD11B1NQO2 | |
| SCHEMBL700051 | 1.00 | NFE2L2 (0.78) | NFE2L2PTGS1APPHSD11B1NQO2 | |
| SCHEMBL13766558 | 1.00 | NFE2L2 (0.78) | NFE2L2PTGS1APPHSD11B1NQO2 | |
| SCHEMBL13766470 | 1.00 | NFE2L2 (0.78) | NFE2L2PTGS1APPHSD11B1NQO2 | |
| SCHEMBL13267809 | 0.91 | NFE2L2 (0.67) | NFE2L2PTGS1APPHSD11B1NQO2 | |
| SCHEMBL700760 | 0.88 | NFE2L2 (1.00) | NFE2L2PTGS1APP | |
| SCHEMBL700761 | 0.88 | NFE2L2 (1.00) | NFE2L2PTGS1APP | |
| SCHEMBL18867936 | 0.88 | NFE2L2 (1.00) | NFE2L2PTGS1APP | |
| SCHEMBL4946969 | 0.88 | NFE2L2 (1.00) | NFE2L2PTGS1APP | |
| SCHEMBL9970459 | 0.87 | NFE2L2 (0.62) | NFE2L2PTGS1APPHSD11B1NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115197036-B | Method for performing anti-mahalanobis hydrogen carboxylation reaction on photocatalytic olefin compound and carbon dioxide | 中国科学院理化技术研究所 | 2024-01-23 | — | — | CN | disclosed |
| EP-2810198-B1 | ANTI-INVASIVE COMPOUNDS | UNIV GENT (BE) | 2023-07-12 | — | — | EP | disclosed |
| US-9616099-B2 | Cyclosporin analogues for preventing or treating hepatitis C infection | ENANTA PHARMACEUTICALS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| EP-3038626-A1 | CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C | Enanta Pharmaceuticals, Inc. (US) | 2016-07-06 | — | — | EP | disclosed |
| US-20160136233-A1 | NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | ENANTA PHARM INC (US) | 2016-05-19 | — | — | US | disclosed |
| US-9290427-B2 | Anti-invasive compounds | UNIVERSITEIT GENT (BE) | 2016-03-22 | — | — | US | disclosed |
| US-9221878-B2 | Cyclosporin analogues for preventing or treating hepatitis C infection | ENANTA PHARMACEUTICALS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| WO-2015031381-A1 | CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C | ENANTA PHARMACEUTICALS, INC. (US) | 2015-03-05 | — | — | WO | disclosed |
| US-20150056165-A1 | NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | ENANTA PHARMACEUTICALS, INC. | 2015-02-26 | — | — | US | disclosed |
| US-20150011620-A1 | ANTI-INVASIVE COMPOUNDS | UNIVERSITEIT GENT (BE) | 2015-01-08 | — | — | US | disclosed |
| US-4980367-A | CONTROLLING PLANT DISEASES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-12-25 | — | — | US | disclosed |
| EP-0390850-A4 | ANTIFUNGAL CARBINOLS | — | 1990-12-05 | — | — | EP | disclosed |
| EP-0390850-A1 | ANTIFUNGAL CARBINOLS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1990-10-10 | — | — | EP | disclosed |
| EP-0193055-B1 | ANTITUMORALS(1,2-DIPHENYL-ETHYLENE DIAMINE)-PLATINUM (II) COMPLEXES | ASTA Pharma AG (DE) | 1990-05-16 | — | — | EP | disclosed |
| WO-1989005801-A1 | ANTIFUNGAL CARBINOLS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-06-29 | — | — | WO | disclosed |
| WO-1989005581-A1 | ANTIFUNGAL CARBINOLS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-06-29 | — | — | WO | disclosed |
| EP-0321211-A1 | Antifungal carbinols | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-06-21 | — | — | EP | disclosed |
| EP-0251086-A2 | Antifungal carbinols | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1988-01-07 | — | — | EP | disclosed |
| EP-0193055-A1 | Antitumorals(1,2-diphenyl-ethylene diamine)-platinum (II) complexes | ASTA Pharma AG (DE) | 1986-09-03 | — | — | EP | disclosed |
| US-3972944-A | BORON OXIDE, BORIC ACID OR BORATE AND VANADIUM OR MOLYBDENUM CONTAINING CATALYST | BAYER AKTIENGESELLSCHAFT (DT) | 1976-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160136233-A1 | NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | HAVCR2, CHP1, MAVS | NFE2L2 3069/4885PTGS1 2502/4885APP 2998/4885 |
| US-20150011620-A1 | ANTI-INVASIVE COMPOUNDS | MMP3, MMP10, MIF | NFE2L2 1215/4885PTGS1 258/4885APP 4234/4885 |
| US-20150056165-A1 | NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | HAVCR2, CHP1, MAVS | NFE2L2 3069/4885PTGS1 2502/4885APP 2998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.